Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$21.89 +1.6%	$23.88	$14.96 ▼ $26.58	$2.63B	0.72	1.11 million shs	1.02 million shs
CRNX Crinetics Pharmaceuticals	$29.99 -1.4%	$31.48	$24.10 ▼ $62.53	$2.85B	0.28	833,109 shs	532,620 shs
HROW Harrow	$31.35 -0.6%	$27.48	$20.36 ▼ $59.23	$1.16B	0.4	495,535 shs	333,122 shs
SLNO Soleno Therapeutics	$84.02 -2.1%	$76.32	$39.41 ▼ $86.67	$4.32B	-2.69	786,922 shs	1.04 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	+1.62%	-4.03%	-11.88%	-11.34%	+45.16%
CRNX Crinetics Pharmaceuticals	-1.38%	-1.67%	+1.66%	-13.65%	-28.92%
HROW Harrow	-0.63%	-0.54%	+19.07%	+19.61%	+46.91%
SLNO Soleno Therapeutics	-2.06%	+5.85%	+10.18%	+16.71%	+112.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.9305 of 5 stars	3.6	2.0	3.9	3.3	3.3	3.8
CRNX Crinetics Pharmaceuticals	3.6419 of 5 stars	3.5	0.0	3.7	3.3	2.5	0.0
HROW Harrow	2.4515 of 5 stars	3.5	1.0	0.0	2.8	2.5	0.6
SLNO Soleno Therapeutics	4.7093 of 5 stars	4.5	3.0	4.6	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	49.99% Upside
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	148.60% Upside
HROW Harrow	3.00	Buy	$61.40	95.85% Upside
SLNO Soleno Therapeutics	3.09	Buy	$107.10	27.47% Upside

Current Analyst Ratings Breakdown

Latest HROW, SLNO, CRNX, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	SLNO Soleno Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/23/2025	SLNO Soleno Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$110.00
6/12/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$62.00
6/10/2025	HROW Harrow	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	HROW Harrow	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$57.00 ➝ $60.00
5/8/2025	SLNO Soleno Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$81.00 ➝ $97.00
5/8/2025	SLNO Soleno Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$102.00 ➝ $105.00
4/24/2025	SLNO Soleno Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$93.00 ➝ $145.00
4/15/2025	SLNO Soleno Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
4/1/2025	HROW Harrow	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$69.00 ➝ $65.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$491.73M	5.43	$2.49 per share	8.80	$6.10 per share	3.59
CRNX Crinetics Pharmaceuticals	$1.04M	2,699.97	N/A	N/A	$14.29 per share	2.10
HROW Harrow	$199.61M	5.76	$0.14 per share	230.73	$1.95 per share	16.08
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.57	13.94	10.28	0.88	36.91%	42.45%	36.59%	8/6/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-30.95%	-28.12%	8/6/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.56	N/A	78.38	N/A	-10.19%	-25.01%	-4.27%	8/6/2025 (Estimated)
SLNO Soleno Therapeutics	-$175.85M	-$4.62	N/A	N/A	N/A	N/A	-77.52%	-63.44%	8/6/2025 (Estimated)

Latest HROW, SLNO, CRNX, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
5/8/2025	Q1 2025	HROW Harrow	$0.02	-$0.38	-$0.40	-$0.50	$57.00 million	$47.83 million
5/7/2025	Q1 2025	SLNO Soleno Therapeutics	-$1.14	-$0.95	+$0.19	-$0.95	N/A	N/A
3/27/2025	Q4 2024	HROW Harrow	$0.11	$0.25	+$0.14	$0.24	$66.01 million	$66.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.14	5.96
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
HROW Harrow	2.01	0.91	0.85
SLNO Soleno Therapeutics	0.21	19.64	19.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
CRNX Crinetics Pharmaceuticals	98.51%
HROW Harrow	72.76%
SLNO Soleno Therapeutics	97.42%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
CRNX Crinetics Pharmaceuticals	4.60%
HROW Harrow	15.16%
SLNO Soleno Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	121.97 million	109.29 million	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	89.32 million	Optionable
HROW Harrow	182	36.69 million	31.12 million	Optionable
SLNO Soleno Therapeutics	30	50.39 million	47.17 million	Optionable

HROW, SLNO, CRNX, and CPRX Headlines

Recent News About These Companies

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $22,410.50 in Stock

5 hours ago | marketbeat.com

SLNO Soleno Therapeutics, Inc. - Seeking Alpha

June 25 at 10:31 AM | seekingalpha.com

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference

June 25 at 10:31 AM | santelog.comS

Soleno gains as Betaville cites buyout interest (update)

June 24 at 7:28 PM | msn.com

Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year High - Here's What Happened

June 23, 2025 | marketbeat.com

Soleno Therapeutics initiated with a Buy at TD Cowen

June 23, 2025 | msn.com

FDA Approval for its Drug Lifted Soleno Therapeutics (SLNO) Shares by 60%

June 23, 2025 | msn.com

Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated at TD Cowen

June 23, 2025 | marketbeat.com

Soleno Therapeutics: Overbought On VYKAT Approval Enthusiasm

June 22, 2025 | seekingalpha.com

GAMMA Investing LLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

June 22, 2025 | marketbeat.com

Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects

June 20, 2025 | msn.com

Soleno Therapeutics to Present Research Findings at 2025 International Prader-Willi Syndrome Conference

June 20, 2025 | quiverquant.comQ

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

June 20, 2025 | globenewswire.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Buy" from Brokerages

June 14, 2025 | marketbeat.com

434,514 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Assenagon Asset Management S.A.

June 13, 2025 | marketbeat.com

Soleno Therapeutics (NASDAQ:SLNO) Sets New 12-Month High - Here's What Happened

June 12, 2025 | marketbeat.com

These 24 Stocks Are Ripe for a Short Squeeze

June 12, 2025 | schaeffersresearch.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Harbor Capital Advisors Inc.

June 11, 2025 | marketbeat.com

California State Teachers Retirement System Has $988,000 Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on SLNO FY2026 Earnings

June 10, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 5,462 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

June 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW, SLNO, CRNX, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.89 +0.35 (+1.62%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$22.05 +0.16 (+0.73%)

As of 06/26/2025 07:57 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Crinetics Pharmaceuticals NASDAQ:CRNX

$29.99 -0.42 (-1.38%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$30.00 +0.01 (+0.03%)

As of 06/26/2025 06:03 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Harrow NASDAQ:HROW

$31.35 -0.20 (-0.63%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$31.12 -0.24 (-0.75%)

As of 06/26/2025 07:56 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Soleno Therapeutics NASDAQ:SLNO

$84.02 -1.77 (-2.06%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$84.02 0.00 (0.00%)

As of 06/26/2025 05:07 PM Eastern

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time